Publications:

Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI.

Frontiers In Oncology

Zhang, He H; Dong, Weiwei W; Zhao, Huixia H; Hu, Yanyan Y; You, Xia X; Sun, Tingting T; Xiao, Wenhua W

Publication Date: 2022

Variant appearance in text: EGFR: F287_G288insHA

PubMed Link: 35251994

Variant Present in the following documents:

• Main text
• fonc-12-826938.pdf

View BVdb publication page